Home › Targets › VEGF
VEGF (6 companies · 24 programs)
Companies with an active program directed at VEGF.
- CR-001 — Non-Small Cell Lung Cancer Phase 2
- CR-001 — Hepatocellular Carcinoma Phase 1
- CR-001 — Biliary Tract Cancer Phase 1
- CR-001 — Gastric Cancer Phase 1
- CR-001 — Colorectal Cancer Phase 1
- CR-001 — Endometrial Carcinoma Phase 1
- CR-001 — Cervical Cancer Phase 1
- CR-001 — Ovarian Cancer Phase 1
- Zenkuda — Wet Age-Related Macular Degeneration Phase 3
- Zenkuda — Diabetic Retinopathy Phase 3
- Zenkuda — Retinal Vein Occlusion Phase 3
- KSI-501 — Wet Age-Related Macular Degeneration Phase 3
- KSI-101 — Macular Edema Secondary to Inflammation Phase 3
- KSI-501 — Diabetic Macular Edema Phase 3
- ivonescimab — Non-Small Cell Lung Cancer NDA Submitted
- ivonescimab — Colorectal Cancer Phase 3
- ivonescimab — Head and Neck Squamous Cell Carcinoma Phase 3
- ivonescimab — Urothelial Carcinoma Phase 2
- LYTENAVA — Wet Age-Related Macular Degeneration Approved
- LYTENAVA — Diabetic Macular Edema Phase 3
- LYTENAVA — Branch Retinal Vein Occlusion Phase 3
- DURAVYU — Wet Age-Related Macular Degeneration Phase 3
- DURAVYU — Diabetic Macular Edema Phase 3
- 4D-150 — Wet Age-Related Macular Degeneration Phase 3
